Cancer Vaccine Moves Closer to FDA Approval

With the news of Dendreon Corporation's announcement yesterday at the annual meeting in Chicago of the American Urological Association that its investigational active cellular immunotherapy for advanced prostate cancer, PROVENGE (sipuleucel-T), extended patient survival by 4.1 months and increased 3-year survival by 38 percent compared to placebo, the field of tumor immunology has taken a significant leap forward as this, the first active cellular immunotherapy shown in a phase III clinical trial to benefit patients, moves closer to FDA approval.

According to experts in the field of tumor immunology, this is an important milestone achievement--within the scope of the history of tumor immunology and the decades of effort to bring effective cancer immunotherapies to patients, the impact of PROVENGE specifically on prostate cancer therapy today, and the broader import this has and as it bears on cancer vaccine discovery and development efforts currently underway within academic and industry domains.

The Cancer Research Institute, a non-profit organization the supports and coordinates laboratory and clinical efforts leading to the immunological treatment, control, and prevention of cancer, is a global leader in cancer vaccine development. The CRI/LICR Cancer Vaccine Collaborative--a centralized network of more than 20 top academic clinical trial sites with immunological monitoring capability engaged in single-variable, first-in-man cancer vaccine studies, formed in partnership with the Ludwig Institute for Cancer Research Ltd--and its Cancer Vaccine Consortium--a membership association of more than 60 pharmaceutical and biotechnology companies and academic institutions who share a common goal of making cancer vaccines part of the standard-of-care for cancer patients--together comprise the world's leading experts in cancer vaccine discovery and development from both academia and industry.

Cancer Research Institute can provide expert commentary on the importance of the PROVENGE study results and what they mean for the field of tumor immunology, for cancer patients, and for the future of cancer therapy, as well as key challenges still facing the field, including vaccine reagent access, intellectual property concerns, regulatory issues, protocol design, RECIST criteria, and strategies that work to bridge the divide between academic and industry interests.

Suggested Expert:

Lloyd J. Old, M.D.

Lloyd J. Old, M.D., is chairman of the Board of Directors of the Ludwig Institute for Cancer Research Ltd. Previously, he was director and chief executive officer of the Ludwig Institute. He has been associated with the Memorial Sloan-Kettering Cancer Center since 1958, first as a research fellow. He was appointed associate director of research in 1973 of Memorial Sloan-Kettering Cancer Center and Memorial Hospital for Cancer and Allied Diseases and was named the William E. Snee Chair of Cancer Immunology in 1983.

Lloyd J. Old, M.D., is one of the pioneers in tumor immunology, having made some of the most important contributions to that field from both the lab bench and the board room table. He is one of the most highly cited researchers in the field, and is an international award-winning scientific luminary who has helped to forge alliances among academic and industry interests in order to accelerate the scientifically prudent advancement of cancer vaccines.

For a more detailed biography of Dr. Old, visit:
http://www.cancerresearch.org/board/Lloyd-Old.html

For a description of Dr. Old's key scientific contributions, visit:
http://www.cancerresearch.org/Programs.aspx?id=2290

Views: 44

Comment

You need to be a member of 12160 Social Network to add comments!

Join 12160 Social Network

"Destroying the New World Order"

TOP CONTENT THIS WEEK

THANK YOU FOR SUPPORTING THE SITE!

mobile page

12160.info/m

12160 Administrators

 

Latest Activity

Doc Vega posted a blog post

Terror on All Hallows Eve

Chapter IElizabeth was angry. All of her friends were going to be out on Halloween, but her. She…See More
3 hours ago
Jeff favorited Jeff's profile
19 hours ago
Jeff favorited Jeff's profile
19 hours ago
Jeff favorited Doc Vega's profile
19 hours ago
Jeff is now a member of 12160 Social Network
yesterday
Doc Vega posted blog posts
Friday
tjdavis posted a video

How Corporations Are Secretly Poisoning Our Food Supply

Dupont and 3M have been secretly poisoning America for decades. PFAs — also known as forever chemicals—are now in our food, water, clothes, and our blood. Th...
Friday
Doc Vega posted a blog post

They Won’t Stop

 The demonically driven left will not stop. Makes no difference how much violence they call for or…See More
Wednesday
Doc Vega posted a blog post

What US Scientist unwittingly helped the Nazis devise the V-2 Missile?

  In the early 1920’s and leading up to World War II German technology outpaces the peace time…See More
Oct 20
tjdavis favorited Sandy's video
Oct 19
tjdavis posted a photo
Oct 19
Christopher Walker is now a member of 12160 Social Network
Oct 19
tjdavis posted videos
Oct 19
Burbia commented on tjdavis's photo
Thumbnail

Reflection

"Let's see if this goes past indictment."
Oct 18
Doc Vega commented on Doc Vega's blog post Something Watches From Out there in the Wilderness
"cheeki kea That's very interesting history. So many things about history that go ignored or…"
Oct 18
Burbia commented on Burbia's video
Oct 18
Burbia posted a video

Programmed To Kill/Satanic Cover-Up Part 433 (The Charlie Kirk Conspiracy Show)

https://www.programmedtokill.net/projects---- DISCLAIMER! ----Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for "fair u...
Oct 18
cheeki kea commented on cheeki kea's photo
Thumbnail

American werewolf- 2018

"Yip I've looked again and this is what the creature looks like, even has stripes just like…"
Oct 18
cheeki kea commented on cheeki kea's photo
Thumbnail

American werewolf- 2018

"The mystery continues I guess. ( reminds me of something out of the under world )"
Oct 18
cheeki kea posted a photo
Oct 18

© 2025   Created by truth.   Powered by

Badges  |  Report an Issue  |  Terms of Service

content and site copyright 12160.info 2007-2019 - all rights reserved. unless otherwise noted